ArticleMolecular therapy. Methods & clinical development2025
Characterization of factors that influence rAAV yield and quality when produced using rHSV co-infection.
Article in Molecular therapy. Methods & clinical development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic gene therapy requires administration of recombinant adeno-associated virus (rAAV) at high viral doses to maximize delivery of the therapeutic transgene. Efforts to improve and evolve rAAV production to increase yield and quality are an important focus in the field, with the goal to mitigate the manufacturing burden for clinical use. In this study, several factors were assessed for their impact on rAAV production using herpes simplex virus (HSV) in a shake flask system. Recombinant HSV (rHSV) for gene of interest (rHSV-GOI) and Rep-Cap (rHSV-RC) were used for co-infection of HEK293 cells, and yield and quality attributes were measured. rHSV multiplicity of infection (MOI) and choice of cell culture medium had a significant impact on rAAV yield and quality and the sequence of rHSV addition also influenced yield. HSV ICP0 expression was assessed as a surrogate for HSV infectivity and was revealed to be a useful tool that highlighted the complexity of rAAV production using HSV. An unexpected relationship between cell culture medium and HSV infectivity was identified, and this had a significant impact on MOI selection for rAAV production. These data illustrate the value of studies that characterize the biology of HSV infection for rAAV production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.